Alzheimer s disease biomarkers their value in diagnosis and clinical trials
作者： David H Small
DOI: 10.2741/A824
关键词:
摘要: Biomarkers of Alzheimer's disease may be useful, not only for early diagnosis the disease, but also monitoring progress drug trials. A number plasma and cerebrospinal fluid markers are reportedly altered in disease. So far, no single biomarker can used to diagnose definitively. Nevertheless, it eventually possible use several combination obtain sufficient diagnostic accuracy. However, this case, new specific biomarkers need identified.
bioscience.org参考文章(28)
John H. Growdon, Incorporating biomarkers into clinical drug trials in Alzheimer's disease. Journal of Alzheimer's Disease. ,vol. 3, pp. 287- 292 ,(2001) , 10.3233/JAD-2001-3303
Lisa R. Fodero, Javier Sáez-Valero, Maria-Sagrario Barquero, Alberto Marcos, Catriona A. McLean, David H. Small, Wheat germ agglutinin-binding glycoproteins are decreased in Alzheimer's disease cerebrospinal fluid Journal of Neurochemistry. ,vol. 79, pp. 1022- 1026 ,(2008) , 10.1046/J.1471-4159.2001.00640.X
N.C. Fox, M.N. Rossor, Seeing what alzheimer saw-with magnetic resonance microscopy Nature Medicine. ,vol. 6, pp. 20- 21 ,(2000) , 10.1038/71481
Dale Schenk, Robin Barbour, Whitney Dunn, Grace Gordon, Henry Grajeda, Teresa Guido, Kang Hu, Jiping Huang, Kelly Johnson-Wood, Karen Khan, Dora Kholodenko, Mike Lee, Zhenmei Liao, Ivan Lieberburg, Ruth Motter, Linda Mutter, Ferdie Soriano, George Shopp, Nicki Vasquez, Christopher Vandevert, Shannan Walker, Mark Wogulis, Ted Yednock, Dora Games, Peter Seubert, Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. ,vol. 400, pp. 173- 177 ,(1999) , 10.1038/22124
Malcolm L. Kennard, Howard Feldman, Tatsuo Yamada, Wilfred A. Jefferies, Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nature Medicine. ,vol. 2, pp. 1230- 1235 ,(1996) , 10.1038/NM1196-1230
N. Rosler, I. Wichart, K. A. Jellinger, Intra vitam lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukin-6 in Alzheimer's disease patients. Acta Neurologica Scandinavica. ,vol. 103, pp. 126- 130 ,(2001) , 10.1034/J.1600-0404.2001.103002126.X
R. Motter, C. Vigo-Pelfrey, D. Kholodenko, R. Barbour, K. Johnson-Wood, D. Galasko, L. Chang, B. Miller, C. Clark, R. Green, D. Olson, P. Southwick, R. Wolfert, B. Munroe, I. Lieberburg, P. Seubert, D. Schenk, Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease Annals of Neurology. ,vol. 38, pp. 643- 648 ,(1995) , 10.1002/ANA.410380413
John H. Growdon, Biomarkers of Alzheimer disease. JAMA Neurology. ,vol. 56, pp. 281- 283 ,(1999) , 10.1001/ARCHNEUR.56.3.281
Eleftherios P Diamandis, George M Yousef, Constantina Petraki, Antoninus R Soosaipillai, Human Kallikrein 6 as a Biomarker of Alzheimer’s Disease Clinical Biochemistry. ,vol. 33, pp. 663- 667 ,(2000) , 10.1016/S0009-9120(00)00185-5
S M Monte, K Ghanbari, W H Frey, I Beheshti, P Averback, S L Hauser, H A Ghanbari, J R Wands, Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid Journal of Clinical Investigation. ,vol. 100, pp. 3093- 3104 ,(1997) , 10.1172/JCI119864